SG11201703152RA - Reducing viscosity of pharmaceutical formulations - Google Patents

Reducing viscosity of pharmaceutical formulations

Info

Publication number: SG11201703152RA
Authority: SG; Singapore
Prior art keywords: pharmaceutical formulations; reducing viscosity; viscosity; reducing; formulations
Prior art date: 2014-10-23

Application number

SG11201703152RA

Inventor

Christopher James Sloey

Sekhar Kanapuram

Original Assignee

Amgen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-10-23

Filing date

2015-10-22

Publication date

2017-05-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54427875&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201703152R(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-10-22 Application filed by Amgen Inc filed Critical Amgen Inc

2017-05-30 Publication of SG11201703152RA publication Critical patent/SG11201703152RA/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Immunology (AREA)
Mycology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Oil, Petroleum & Natural Gas (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

SG11201703152RA 2014-10-23 2015-10-22 Reducing viscosity of pharmaceutical formulations SG11201703152RA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201462067637P	2014-10-23	2014-10-23
PCT/US2015/056972 WO2016065181A1 (en)	2014-10-23	2015-10-22	Reducing viscosity of pharmaceutical formulations

Publications (1)

Publication Number	Publication Date
SG11201703152RA true SG11201703152RA (en)	2017-05-30

Family

ID=54427875

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201703152RA SG11201703152RA (en)	2014-10-23	2015-10-22	Reducing viscosity of pharmaceutical formulations

Country Status (17)

Country	Link
US (3)	US11813328B2 (en)
EP (2)	EP3209332B1 (en)
JP (3)	JP2017531682A (en)
KR (1)	KR102534017B1 (en)
CN (2)	CN114569716A (en)
AU (2)	AU2015335743B2 (en)
BR (1)	BR112017008125B1 (en)
CA (1)	CA2964786C (en)
CL (2)	CL2017000984A1 (en)
EA (3)	EA202191513A1 (en)
ES (1)	ES2964713T3 (en)
IL (2)	IL287947B2 (en)
MA (1)	MA54716A (en)
MX (2)	MX388858B (en)
SG (1)	SG11201703152RA (en)
WO (1)	WO2016065181A1 (en)
ZA (1)	ZA201702762B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3209332B1 (en)	2014-10-23	2021-05-26	Amgen Inc.	Reducing viscosity of pharmaceutical formulations
US11459401B2 (en)	2016-10-06	2022-10-04	Amgen Inc.	Reduced viscosity protein pharmaceutical formulations
JP7377596B2 (en) *	2017-02-22	2023-11-10	アムジエン・インコーポレーテツド	Low viscosity, high concentration evolocumab formulations and their manufacturing method
US12257343B2 (en)	2017-04-28	2025-03-25	Amgen Inc.	Excipients to reduce the viscosity of antibody formulations and formulation compositions
US12103979B2 (en) *	2017-04-28	2024-10-01	Amgen Inc.	N-acetylated and non-acetylated dipeptides containing arginine to reduce the viscosity of viscous compositions of therapeutic polypeptides
CA3063324A1 (en)	2017-05-16	2018-11-22	Bhami's Research Laboratory, Pvt. Ltd.	High concentration protein formulations with reduced viscosity
ES2894629T3 (en)	2017-06-16	2022-02-15	Zealand Pharma As	Dosage Guidelines for Administration of Glucagon-Like Peptide-2 (GLP-2) Analogues
JP6577683B2 (en) *	2017-09-22	2019-09-18	旭化成ファーマ株式会社	Liquid pharmaceutical composition containing teriparatide having excellent stability
WO2019106206A1 (en)	2017-12-01	2019-06-06	Fyb 202 Project Gmbh	Stable, low viscosity, high concentration liquid formulations of an anti-il-12/23p40 antibody
PE20210462A1 (en)	2018-07-05	2021-03-08	Bayer Ag	METHOD FOR THE PRODUCTION OF LYOPHILIZED GRANULES THAT INCLUDE AN ANTI-FACTOR XIa (FXIa) ANTIBODY OF COAGULATION
MY204234A (en)	2018-08-27	2024-08-16	Regeneron Pharma	Use of raman spectroscopy in downstream purification
EP3628683A1 (en) *	2018-09-28	2020-04-01	Zealand Pharma A/S	Formulations of glucagon-like-peptide-2 (glp-2) analogues
CA3141857A1 (en) *	2019-04-23	2020-10-29	Amgen Inc.	The use of low molecular weight polyvinylpyrrolidone (pvp) to reduce viscosity of high concentration protein formulations
KR20220140772A (en) *	2020-02-13	2022-10-18	암젠 인크	Human anti-TSLP antibody formulations and methods of treatment of inflammatory diseases
KR102746418B1 (en) *	2020-12-03	2024-12-26	동국대학교 산학협력단	Composition for inhibiting aggregation of protein comprising N-acetyl-L-arginine
JP2024509937A (en) *	2021-03-09	2024-03-05	ジーアイ・イノベイション・インコーポレイテッド	Formulation of a fusion protein containing the extracellular domain of the alpha subunit of the IGE FC receptor
WO2022217021A1 (en) *	2021-04-09	2022-10-13	Avantor Performance Materials, Llc	Performance-enhancing excipients and methods of reducing viscosity and increasing stability of biologic formulations
WO2025175164A1 (en) *	2024-02-16	2025-08-21	Regeneron Pharmaceuticals, Inc.	Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5078997A (en)	1988-07-13	1992-01-07	Cetus Corporation	Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
US5955448A (en)	1994-08-19	1999-09-21	Quadrant Holdings Cambridge Limited	Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
US6767892B1 (en) *	1997-11-07	2004-07-27	Chrion Corporation	Compositions providing for increased IGF-I solubility
DE69814133T2 (en)	1997-11-07	2004-04-01	Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville	COMPOSITION TO INCREASE THE SOLUBILITY OF IGF-I
US6660843B1 (en)	1998-10-23	2003-12-09	Amgen Inc.	Modified peptides as therapeutic agents
US6159485A (en) *	1999-01-08	2000-12-12	Yugenic Limited Partnership	N-acetyl aldosamines, n-acetylamino acids and related n-acetyl compounds and their topical use
MXPA02009485A (en)	2000-03-31	2003-03-10	Kirin Brewery	Powdery preparation for transmucosal administration containing a polymeric form of drug and exhibiting improved storage stability.
DE60139339D1 (en)	2000-11-07	2009-09-03	Novartis Vaccines & Diagnostic	STABILIZED INTERFERON COMPOSITIONS
WO2003017935A2 (en)	2001-08-23	2003-03-06	Genmab A/S	Human antibodies specific for interleukin 15 (il-15)
DK1478394T3 (en)	2002-02-27	2008-10-13	Immunex Corp	Stabilized TNFR-Fc formulation with arginine
US20040191243A1 (en)	2002-12-13	2004-09-30	Bei Chen	System and method for stabilizing antibodies with histidine
JP2006516636A (en)	2003-01-30	2006-07-06	メディミューン，インコーポレーテッド	Anti-integrin αvβ3 antibody preparation and use thereof
DK2335725T3 (en)	2003-04-04	2017-01-23	Genentech Inc	Highly concentrated antibody and protein formulations
US8084032B2 (en)	2004-01-21	2011-12-27	Ajinomoto Co., Inc.	Purification method which prevents denaturation of an antibody
US20060051347A1 (en)	2004-09-09	2006-03-09	Winter Charles M	Process for concentration of antibodies and therapeutic products thereof
AU2006208226A1 (en)	2005-01-24	2006-08-03	Amgen Inc.	Humanized anti-amyloid antibody
US8003108B2 (en)	2005-05-03	2011-08-23	Amgen Inc.	Sclerostin epitopes
US7592429B2 (en)	2005-05-03	2009-09-22	Ucb Sa	Sclerostin-binding antibody
US9084777B2 (en)	2005-12-28	2015-07-21	Chugai Seiyaku Kabushiki Kaisha	Stabilized antibody-containing formulations
CN101426527A (en) *	2006-02-03	2009-05-06	米迪缪尼有限公司	Protein formulations
GB0603683D0 (en)	2006-02-23	2006-04-05	Novartis Ag	Organic compounds
ES2389737T3 (en)	2006-05-11	2012-10-31	Isis Pharmaceuticals, Inc.	5 'modified bicyclic nucleic acid analogs
EP2628752A1 (en)	2006-12-14	2013-08-21	Merck Sharp & Dohme Corp.	Engineered anti-TSLP antibody
AR067045A1 (en)	2007-06-20	2009-09-30	Irm Llc	METHODS AND COMPOSITIONS FOR THE TREATMENT OF ALLERGIC DISEASES
JOP20080381B1 (en)	2007-08-23	2023-03-28	Amgen Inc	Antigen Binding Proteins to Proprotein Convertase subtillisin Kexin type 9 (pcsk9)
US7982016B2 (en)	2007-09-10	2011-07-19	Amgen Inc.	Antigen binding proteins capable of binding thymic stromal lymphopoietin
KR20150080038A (en)	2007-11-30	2015-07-08	애브비 바이오테크놀로지 리미티드	Protein formulations and methods of making same
KR20100120289A (en) *	2008-01-15	2010-11-15	애보트 게엠베하 운트 콤파니 카게	Powdered protein compositions and methods of making same
TWI445716B (en)	2008-09-12	2014-07-21	Rinat Neuroscience Corp	Pcsk9 antagonists
JO3672B1 (en)	2008-12-15	2020-08-27	Regeneron Pharma	High Affinity Human Antibodies to PCSK9
JP2011067202A (en)	2009-08-31	2011-04-07	Sanyo Chem Ind Ltd	Stabilizer for aqueous protein solution, aqueous protein solution containing the same, and method for stabilization of protein
CA2780554C (en) *	2009-11-17	2017-08-15	Ipsen Pharma S.A.S.	Formulation for hgh and rhigf-1 combination
EP2531218B1 (en)	2010-02-04	2018-12-12	CSL Behring AG	Immunoglobulin preparation
BR112012021576A2 (en) *	2010-02-26	2016-10-25	Novo Nordisk As	stable antibody-containing compositions.
US20130171128A1 (en) *	2010-03-02	2013-07-04	Amgen Inc.	Reducing viscosity of pharmaceutical formulations
WO2011139718A1 (en)	2010-05-03	2011-11-10	Genentech, Inc.	Compositions and methods useful for reducing the viscosity of protein-containing formulations
UY33679A (en)	2010-10-22	2012-03-30	Esbatech	STABLE AND SOLUBLE ANTIBODIES
JOP20200043A1 (en)	2011-05-10	2017-06-16	Amgen Inc	Ways to treat or prevent cholesterol disorders
WO2013012022A1 (en)	2011-07-19	2013-01-24	中外製薬株式会社	Stable protein-containing preparation containing argininamide or analogous compound thereof
AU2012328524B2 (en) *	2011-10-28	2017-05-18	Excelse Bio, Inc.	Protein formulations containing amino acids
EA039663B1 (en)	2012-05-03	2022-02-24	Амген Инк.	Use of an anti-pcsk9 antibody for lowering serum cholesterol ldl and treating cholesterol related disorders
US20150150982A1 (en)	2012-06-12	2015-06-04	Boehringer Ingelheim International Gmbh	Pharmaceutical formulation for a therapeutic antibody
US20150004174A1 (en)	2013-06-28	2015-01-01	Amgen Inc.	Methods for treating homozygous familial hypercholesterolemia
TWI694836B (en)	2014-05-16	2020-06-01	英商葛蘭素史克智慧財產管理有限公司	Antibody formulation
EP3209332B1 (en)	2014-10-23	2021-05-26	Amgen Inc.	Reducing viscosity of pharmaceutical formulations
CN106999588A (en)	2014-12-03	2017-08-01	瑞士杰特贝林生物制品有限公司	The drug products for including immunoglobulin with increased stability
CA3038909A1 (en)	2016-09-29	2018-04-05	Amgen Inc.	Low-viscosity antigen binding proteins and methods of making them
US11459401B2 (en)	2016-10-06	2022-10-04	Amgen Inc.	Reduced viscosity protein pharmaceutical formulations
JP7377596B2 (en)	2017-02-22	2023-11-10	アムジエン・インコーポレーテツド	Low viscosity, high concentration evolocumab formulations and their manufacturing method

2015
- 2015-10-22 EP EP15790759.3A patent/EP3209332B1/en active Active
- 2015-10-22 ES ES21175309T patent/ES2964713T3/en active Active
- 2015-10-22 AU AU2015335743A patent/AU2015335743B2/en active Active
- 2015-10-22 CN CN202210048275.7A patent/CN114569716A/en active Pending
- 2015-10-22 EA EA202191513A patent/EA202191513A1/en unknown
- 2015-10-22 CA CA2964786A patent/CA2964786C/en active Active
- 2015-10-22 IL IL287947A patent/IL287947B2/en unknown
- 2015-10-22 CN CN201580057461.5A patent/CN107206070B/en active Active
- 2015-10-22 JP JP2017522169A patent/JP2017531682A/en active Pending
- 2015-10-22 EA EA201790787A patent/EA033444B1/en not_active IP Right Cessation
- 2015-10-22 US US15/521,057 patent/US11813328B2/en active Active
- 2015-10-22 WO PCT/US2015/056972 patent/WO2016065181A1/en not_active Ceased
- 2015-10-22 SG SG11201703152RA patent/SG11201703152RA/en unknown
- 2015-10-22 MX MX2017005243A patent/MX388858B/en unknown
- 2015-10-22 EP EP21175309.0A patent/EP3909611B1/en active Active
- 2015-10-22 MA MA054716A patent/MA54716A/en unknown
- 2015-10-22 EA EA201991447A patent/EA038462B1/en unknown
- 2015-10-22 BR BR112017008125-3A patent/BR112017008125B1/en active IP Right Grant
- 2015-10-22 KR KR1020177011706A patent/KR102534017B1/en active Active
2017
- 2017-04-13 IL IL251726A patent/IL251726B/en unknown
- 2017-04-19 ZA ZA2017/02762A patent/ZA201702762B/en unknown
- 2017-04-20 CL CL2017000984A patent/CL2017000984A1/en unknown
- 2017-04-21 MX MX2021015789A patent/MX2021015789A/en unknown
2019
- 2019-08-02 CL CL2019002190A patent/CL2019002190A1/en unknown
- 2019-10-21 JP JP2019191701A patent/JP6965321B2/en active Active
2021
- 2021-02-15 AU AU2021200990A patent/AU2021200990B2/en active Active
- 2021-10-19 JP JP2021170676A patent/JP7411615B2/en active Active
2023
- 2023-10-24 US US18/383,121 patent/US12318447B2/en active Active
2025
- 2025-05-30 US US19/223,578 patent/US20250345421A1/en active Pending

Also Published As

Publication number	Publication date
CL2019002190A1 (en)	2019-11-22
JP2017531682A (en)	2017-10-26
EA201790787A1 (en)	2017-08-31
IL251726B (en)	2021-12-01
JP6965321B2 (en)	2021-11-10
AU2015335743B2 (en)	2020-12-24
ZA201702762B (en)	2022-12-21
CA2964786A1 (en)	2016-04-28
AU2015335743A1 (en)	2017-05-04
US20250345421A1 (en)	2025-11-13
JP7411615B2 (en)	2024-01-11
EA033444B1 (en)	2019-10-31
EP3909611B1 (en)	2023-08-30
CN107206070A (en)	2017-09-26
US20170333559A1 (en)	2017-11-23
CA2964786C (en)	2023-10-17
MA54716A (en)	2021-11-17
MX2021015789A (en)	2022-01-27
AU2021200990A1 (en)	2021-03-11
EA038462B1 (en)	2021-08-31
CL2017000984A1 (en)	2018-01-05
EA202191513A1 (en)	2021-11-30
EP3209332A1 (en)	2017-08-30
KR102534017B1 (en)	2023-05-19
US20240066124A1 (en)	2024-02-29
JP2022009223A (en)	2022-01-14
US12318447B2 (en)	2025-06-03
BR112017008125B1 (en)	2023-11-21
ES2964713T3 (en)	2024-04-09
IL287947A (en)	2022-01-01
WO2016065181A1 (en)	2016-04-28
US11813328B2 (en)	2023-11-14
CN107206070B (en)	2022-01-18
MX388858B (en)	2025-03-20
MX2017005243A (en)	2017-08-18
IL287947B2 (en)	2024-08-01
IL251726A0 (en)	2017-06-29
IL287947B1 (en)	2024-04-01
KR20170071518A (en)	2017-06-23
CN114569716A (en)	2022-06-03
AU2021200990B2 (en)	2023-02-16
EA201991447A1 (en)	2019-11-29
JP2020037559A (en)	2020-03-12
BR112017008125A2 (en)	2018-06-19
EP3909611A1 (en)	2021-11-17
EP3209332B1 (en)	2021-05-26

Publication	Publication Date	Title
IL287947A (en)	2022-01-01	Reducing viscosity of pharmaceutical formulations
IL246978A0 (en)	2016-09-29	Novel pharmaceutical formulations
ZA201605300B (en)	2022-10-26	Pharmaceutical compositions comprising azd9291
GB201618482D0 (en)	2016-12-14	Pharmaceutical compositions
GB201419257D0 (en)	2014-12-10	Pharmaceutical compositions
GB201409471D0 (en)	2014-07-09	Pharmaceutical composition
IL249553A0 (en)	2017-02-28	Pharmaceutical compositions
GB201409488D0 (en)	2014-07-09	Pharmaceutical composition
GB201409485D0 (en)	2014-07-09	Pharmaceutical composition
ZA201606075B (en)	2017-08-30	Pharmaceutical compositions of sitagliptin
IL256115A (en)	2018-02-28	Injectable pharmaceutical formulations of lefamulin
HUE039791T2 (en)	2019-02-28	Pharmaceutical compositions comprising levocetirizine
IL250817A0 (en)	2017-04-30	Pharmaceutical compositions
IL267279A (en)	2019-08-29	Pharmaceutical formulations of suvorexant
GB201718468D0 (en)	2017-12-20	Stable liquid pharmaceutical compositions of bortezomb
PL3200772T3 (en)	2022-12-19	Pharmaceutical compositions comprising alpelisib
GB201506755D0 (en)	2015-06-03	Novel pharmaceutical formulation
LT3089740T (en)	2020-08-10	Pharmaceutical composition
GB2529605B (en)	2018-03-21	Pharmaceutical composition
GB201417589D0 (en)	2014-11-19	Pharmaceutical Formulations
HK1242572A1 (en)	2018-06-29	Reducing viscosity of pharmaceutical formulations
GB201407741D0 (en)	2014-06-18	Novel drug formulation
GB201400951D0 (en)	2014-03-05	Novel drug formulation
SG2014014872A (en)	2014-08-28	Pharmaceutical compositions
GB201408432D0 (en)	2014-06-25	Pharmaceutical compositions